Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan

Table 1

Summary of treatment regimens and duration of response.

Chemotherapy/treatment	Response
(1) Temozolomide and radiation	Partial response after two months, but discontinued secondary to significant thrombocytopenia.
(2) Thalidomide and tamoxifen	Disease stabilization for 10 months with subsequent progression.
(3) Bevacizumab with irinotecan	Significant partial response for 8 months with subsequent progression.
(4) Temozolomide reinduction	Disease progression after 2 months.
(5) Bevacizumab reinduction and pegylated liposomal doxorubicin	Partial response (approximately 60%) after 2 months. Treatment stopped at the patient’s request.